Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance in Age
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: dosage.
- Who it may be relevant to
- Registry conditions: Aging. Basic parameters: 60 years — 99 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance as Well as Variations and Allelic Mutations in the Main Genes Involved in the Occurrence of Age-related Myelodysplastic Syndromes
Overview
Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1.
Detailed description
Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1. After explanations and collection consent, collection of the patient's socio-demographic and medical characteristics and then carrying out a Peripheral venous blood sample (2 x 5ml tubes).
Interventions
- Diagnostic test dosage
Presence of mutation on the gene panel and Frequency of allele variation
Primary outcome measures
- Expression level of LAMP2 (protein and isoform A and B mRNA) [Time frame: day 0]
Secondary outcome measures (1)
- Presence of mutation in the "Oncomin Myeloid Reasearch Assay" gene panel targeting approximately 40 Different genes [Time frame: day 0]
Eligibility criteria
Inclusion criteria
- Men and women over 60 years of age.
Exclusion criteria
- Inability to Understand Consent,
- Non-Security Beneficiaries
- social, subjects protected by law, subjects deprived of liberty,
- history of breast cancer,
- brain tumor,
- melanoma,
- colon cancer,
- lung cancer,
- prostate cancer,
- lymphoma,
- myeloma,
- syndrome myelodysplastic/myeloproliferative,
- leukemia,
- history of radiation therapy.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 1 center
- Chu de Nice — Nice
Identifiers
NCT: NCT06357923 · 23-PP-13 · 2024-A00321-46